compound introduction
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting M pro (IC 50 of 30 nM). In Vivo SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema. SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid
